Forced degradation studies to assess the stability of drugs and products
详细信息 查看全文
- 作者：Saranjit Singh ; Mahendra Junwal ; Gajanan Modhe ; Harsita Tiwari ; Moolch ; Kurmi ; Neha Parashar ; Padmaja Sidduri
- 关键词：AAPH ; 2 ; 2&prime ; -Azobis(2-amidinopropane) dihydrochloride ; ACVA ; 4 ; 4&prime ; -Azobis(4-cyanopentanoicacid) ; AIBN ; Azobisisobutyronitrile ; ANDAs ; Abbreviated new drug applications ; API ; Active pharmaceutical ingredient ; ASEAN ; Association of Southeast Asian
- 刊名：TrAC Trends in Analytical Chemistry
- 出版年：2013
- 出版时间：September, 2013
- 年：2013
- 卷：49
- 期：Complete
- 页码：71-88
- 全文大小：520 K
文摘
A forced degradation study is an essential step in the design of a regulatory compliant stability program for both drug substances and products, and was formalized as a regulatory requirement in ICH Guideline Q1A in 1993. It has since been extended to generic drugs. We provide an update on world-wide regulatory requirements. Also, we list all possible benefits of forced degradation studies to assess the stability of drugs and products. We discuss the kind of forced degradation study likely to meet regulatory expectations. We include the knowledge gained from these studies within the Quality by Design paradigm.